DNA$8.12
Chart
Performance
Key Stats
AI DNA Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldGinkgo Bioworks Holdings, Inc. (DNA) presents a mixed investment profile. While its core business in synthetic biology and potential market growth are compelling, significant financial challenges and a volatile trading history warrant caution. The company operates in a high-growth sector with strong thematic tailwinds, but its current financial position and profitability metrics are concerning.
Thematic
Ginkgo Bioworks is at the forefront of synthetic biology, a rapidly expanding field with applications across pharmaceuticals, agriculture, and industrial biotechnology. The company's platform approach and focus on cell programming position it to benefit from broad secular growth trends.
Fundamental
Ginkgo Bioworks faces significant profitability and cash flow challenges. While revenue has been generated, it has not translated into positive net income, and the company has substantial debt. The current valuation metrics are difficult to interpret due to consistent losses.
Technical
The stock exhibits volatile price action, with significant short-term gains interspersed with sharp pullbacks. While some indicators suggest potential upward momentum, the overall trend and recent price action indicate a cautious approach.
| Factor | Score |
|---|---|
| Synthetic Biology & Bio-engineering | 90 |
| Biosecurity & Health Monitoring | 70 |
| Cross-Industry Applicability | 80 |
| Innovation & Platform Model | 75 |
| Competitive Landscape | 65 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 30 |
| Balance Sheet Health | 50 |
| Cash Flow | 20 |
| Earnings Per Share (EPS) | 10 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 70 |
| Volume Confirmation | 60 |
| Support & Resistance | 75 |
| Short-term Oscillators | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Potential for Undervaluation
The Price-to-Sales (P/S) ratio of 4.6 (TTM) and 5.5 (2025Q1) suggests potential undervaluation relative to historical performance, especially considering the higher P/S of 49.1 in 2021.
Strong Short-Term Performance
The stock has shown significant positive performance over multiple shorter periods (5D: 25.66%, 1M: 48.02%, YTD: 39.19%), indicating recent upward momentum.
Bearish Points (8)
Persistent Net Losses
The company has consistently reported significant net losses across all reported periods (TTM Net Income: -$254,894,000), and negative net margins ranging from -240.9% to -583.1%.
High Price-to-Sales Ratio
The Price-to-Sales (P/S) ratio, while decreasing from 49.1 in 2021, remains high at 4.6 (TTM) and 5.5 (2025Q1), especially for a company with negative net income.
Calendar
May 2025
7
Next Earnings Date
H: $
A: $
L: $
H: 42.70M
A: 41.60M
L: 40.80M
Profile
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Seasonals
Price Target
8.67 USD
The 39 analysts offering 1 year price forecasts for DNA have a max estimate of 12.00 and a min estimate of 6.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Leading synthetic DNA provider, a direct peer and potential competitor or partner to Ginkgo's core bioengineering and DNA synthesis capabilities.
Weight: 92
Dominant player in DNA sequencing technology, which is essential for reading, validating, and developing engineered genetic constructs and understanding biological systems.
Weight: 90
Provides high-performance computing (HPC) and AI platforms crucial for advanced biological design, simulation, and large-scale data analysis in synthetic biology.
Weight: 89
Pioneer in base editing, a highly precise gene-editing technology that directly modifies DNA sequences without cutting, representing advanced DNA manipulation.